Posterior Uveitis – Drugs In Development, 2024
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Posterior Uveitis – Drugs In Development, 2024 report and make more profitable business decisions.
Posterior uveitis refers to intraocular inflammation in the vitreous, retina, or choroid. Chorioretinitis is an inflammation of the choroid (thin pigmented vascular coat of the eye) and retina of the eye. It is a form of posterior uveitis. Inflammation of these layers can lead to vision-threatening complications.
The Posterior Uveitis drugs in development market research report provide comprehensive information on the therapeutics under development for Posterior Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Posterior Uveitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- Therapeutics in Development: Covering 14 molecules, with 14 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Posterior Uveitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Posterior Uveitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Posterior Uveitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acelyrin IncAlumis Inc
BioNanoSim Ltd
Chongqing Kerun Biopharm R & D Co Ltd
Elasmogen Ltd
EyePoint Pharmaceuticals Inc
Eyevensys SAS
Novartis AG
Pharmapraxis
Priovant Therapeutics Inc
Revolo Biotherapeutics Ltd
Tarsier Pharma Ltd
Worg Pharmaceuticals Hangzhou Co Ltd